Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- VIRX
- Price
- 0.02
- Stock movement down
- -0.00 (-17.84%)
- Company name
- Viracta Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 695.52K
- Ent value
- 16.14M
- Price/Sales
- 0.94
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -29.29%
- 1 year return
- -98.46%
- 3 year return
- -84.75%
- 5 year return
- -83.67%
- 10 year return
- -76.35%
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
VIRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.94 |
| Price to Book | - |
| EV to Sales | 21.87 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 39.74M |
| EPS (TTM) | -1.09 |
| FCF per share (TTM) | -1.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 738.00K |
| Gross profit (TTM) | 409.00K |
| Operating income (TTM) | -47.21M |
| Net income (TTM) | -43.29M |
| EPS (TTM) | -1.09 |
| EPS (1y forward) | -0.39 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 55.42% |
| Operating margin (TTM) | -6397.02% |
| Profit margin (TTM) | -5865.72% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.13M |
| Net receivables | 0.00 |
| Total current assets | 21.80M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 21.96M |
| Accounts payable | 1.82M |
| Short/Current long term debt | 16.91M |
| Total current liabilities | 28.57M |
| Total liabilities | 28.57M |
| Shareholder's equity | -6.62M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -34.80M |
| Capital expenditures (TTM) | 9.83M |
| Free cash flow (TTM) | -44.62M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -197.14% |
| Return on Invested Capital | -420.53% |
| Cash Return on Invested Capital | -433.49% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.02 |
| Daily high | 0.03 |
| Daily low | 0.02 |
| Daily Volume | 172K |
| All-time high | 3329423.87 |
| 1y analyst estimate | 3.00 |
| Beta | 0.30 |
| EPS (TTM) | -1.09 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| VIRX | S&P500 | |
| Current price drop from All-time high | -100.00% | -12.89% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 11 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -90.55% | -11.07% |
| Avg time to new high | 492 days | 12 days |
| Max time to new high | 4791 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
695.52K
Marketcap category
Small-cap
Description
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Employees
40
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page